Potential of GLP-1 Agonists in Neurodegeneration: Evidence and Challenges

This chapter explores the promising effects of GLP-1 receptor agonists on neurodegenerative diseases, supported by preclinical evidence of benefits such as decreased inflammation and improved neurogenesis. It also discusses the challenges of translating these lab findings into human clinical trials and highlights epidemiological data suggesting reduced Parkinson's risk in diabetic patients using these treatments.